Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells

Clinical Cancer Research

Volumn 10, Issue 5, 2004, Pages 1860-1869

  Blaszczyk, Natalie ^a   Masri, Bassam A ^c   Mawji, Nasrin R ^a   Ueda, Takeshi ^a   McAlinden, Gavan ^c   Duncan, Clive P ^c   Bruchovsky, Nicholas ^a   Schweikert, Hans Udo ^b   Schnabel, Doris ^b   Jones, Edward C ^c   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BONN   (Germany)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANDROGEN; ANDROGEN RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LUCIFERASE; NEUTRALIZING ANTIBODY; PROSTATE SPECIFIC ANTIGEN; RNA;

AMINO TERMINAL SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE CONSTRUCT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOLECULAR BIOLOGY; NORTHERN BLOTTING; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; REPORTER GENE; TRANSACTIVATION;

ANDROGENS; CELL DIVISION; CELL LINE, TUMOR; GENES, REPORTER; HUMANS; INTERLEUKIN-6; LUCIFERASES; MALE; OSTEOBLASTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 12144288184     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0974-3     Document Type: Article

References (54)

1. Culig, Z., Klocker, H., Bartsch, G., and Hobisch, A. Androgen receptors in prostate cancer. Endocr. Relat. Cancer, 9: 155-170, 2002.
2. Rana, A., Chisholm, G. D., Khan, M., Sekharjit, S. S., Merrick, M. V., and Elton, R. A. Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br. J. Urol., 72: 933-936, 1993.
3. Marks, S. C., and Odgren, P. R. Structure and development of the skeleton. In: J. P. Bilezikian, L. G. Raisz, and G. A. Rodan (eds), Principles of Bone Biology, pp. 3-15. San Diego: Academic Press, 1996.
4. Bova, G. S., Chan-Tack, K. M., and LeCates, W. W. Lethal meta-static human prostate cancer. In: L. W. K. Chung, W. B. Isaacs, and J. W. Simons (eds.), Prostate Cancer: Biology, Genetics, and New Therapeutics, pp. 39-60. Totowa, NJ: Humana Press, Inc., 2001.
5. Lang, S. H., Miller, W. R., and Habib, F. K. Stimulation of human prostate cancer cell lines by factors present in human osteoblast-like cells but not in bone marrow. Prostate, 27: 287-293, 1995.
6. Ueda, T., Bruchovsky, N., and Sadar, M. D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem., 277: 7076-7085, 2002.
7. Ritchie, C. K., Andrews, L. R., Thomas, K. G., Tindall, D. J., and Fitzpatrick, L. A. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology, 138: 1145-1150, 1997.
8. Gleave, M., Hsieh, J. T., Gao, C. A., von Eschenbach, A. C., and Chung, L. W. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 51: 3753-3761, 1991.
9. Steiner, M. S., and Barrack, E. R. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol. Endocrinol., 6: 15-25, 1992.
10. Bentley, H., Hamdy, F. C., Hart, K. A., Seid, J. M., Williams, J. L., Johnstone, D., and Russell, R. G. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer, 66: 1159-1163, 1992.
11. Kimura, G., Kasuya, J., Giannini, S., Honda, Y., Mohan, S., Kawachi, M., Akimoto, M., and Fujita-Yamaguchi, Y. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int. J. Urol., 3: 39-46, 1996.
12. Nakamoto, T., Chang, C. S., Li, A. K., and Chodak, G. W. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res., 52: 571-577, 1992.
13. Chackal-Roy, M., Niemeyer, C., Moore, M., and Zetter, B. R. Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J. Clin. Investig., 84: 43-50, 1989.
14. Ueda, T., Mawji, N. R., Bruchovsky, N., and Sadar, M. D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem., 277: 38087-38094, 2002.
15. Sadar, M. D. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J. Biol. Chem., 274: 7777-7783, 1999.
16. Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G., Klocker, H., and Culig, Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res., 58: 4640-4645, 1998.
17. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., and Klocker, H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res., 54: 5474-5478, 1994.
18. Sadi, M. V., Walsh, P. C., and Barrack, E. R. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer (Phila.), 67: 3057-3064, 1991.
19. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H., and Hittmair, A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res., 55: 3068-3072, 1995.
20. Wilding, G. Endocrine control of prostate cancer. Cancer Surv., 23: 43-62, 1995.
21. Sadar, M. D., Hussain, M., and Bruchovsky, N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr. Relat. Cancer, 6: 487-502, 1999.
22. Adler, H. L., McCurdy, M. A., Kattan, M. W., Timme, T. L., Scardino, P. T., and Thompson, T. C. Elevated levels of circulating interleukin-6 and transforming growth factor-betal in patients with metastatic prostatic carcinoma. J. Urol., 161: 182-187, 1999.
23. Drachenberg, D. E., Elgamal, A. A., Rowbotham, R., Peterson, M., and Murphy, G. P. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate, 41: 127-133, 1999.
24. Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W. S., Kim, W. Y., and Simons, J. W. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 45: 542-549, 1995.
25. Kovacs, E. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed. Pharmacother., 55: 391-396, 2001.
26. Shariat, S. F., Andrews, B., Kattan, M. W., Kim, J., Wheeler, T. M., and Slawin, K. M. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology, 58: 1008-1015, 2001.
27. Kishimoto, T., Akira, S., and Taga, T. Interleukin-6 and its receptor: a paradigm for cytokines. Science (Wash. DC), 258: 593-597, 1992.
28. Okamoto, M., Lee, C., and Oyasu, R. Autocrine effect of androgen on proliferation of an androgen responsive prostatic carcinoma cell line, LNCAP: role of interleukin-6. Endocrinology, 138: 5071-5074, 1997.
29. Klein, B., Zhang, X. G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., and Bataille, R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73: 517-526, 1989.
30. Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett., 250: 607-610, 1989.
31. Yee, C., Biondi, A., Wang, X. H., Iscove, N. N., de Sousa, J., Aarden, L. A., Wong, G. G., Clark, S. C., Messner, H. A., and Minden, M. D. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood, 74: 798-804, 1989.
32. Lu, C., and Kerbel, R. S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell Biol., 120: 1281-1288, 1993.
33. Bellido, T., Jilka, R. L., Boyce, B. F., Girasole, G., Broxmeyer, H., Dalrymple, S. A., Murray, R., and Manolagas, S. C. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J. Clin. Investig., 95: 2886-2895, 1995.
34. Lee, S. O., Lou, W., Hou, M., De Miguel, F., Gerber, L., and Gao, A. C. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer. Res., 9: 370-376, 2003.
35. Rickard, D. J., Kassem, M., Hefferan, T. E., Sarkar, G., Spelsberg, T. C., and Riggs, B. L. Isolation and characterization of osteoblast precursor cells from human bone marrow. J. Bone Miner. Res., 13: 312-324, 1996.
36. Sato, N., Gleave, M. E., Bruchovsky, N., Rennie, P. S., Goldenberg, S. L., Lange, P. H., and Sullivan, L. D. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J. Steroid Biochem. Mol. Biol., 58: 139-146, 1996.
37. Snoek, R., Bruchovsky, N., Kasper, S., Matusik, R. J., Gleave, M., Sato, N., Mawji, N. R., and Rennie, P. S. Differential transactivation by the androgen receptor in prostate cancer cells. Prostate, 36: 256-263, 1998.
38. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
39. Mundy, G. R. Mechanisms of bone metastasis. Cancer (Phila.), 80: 1546-1556, 1997.
40. Lange, P. H., and Vessella, R. L. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev., 17: 331-336, 1998-1999.
41. Bruchovsky, N., Klotz, L. H., Sadar, M., Crook, J. M., Hoffart, D., Godwin, L., Warkentin, M., Gleave, M. E., and Goldenberg, S. L. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol. Urol., 4: 191-199, 2001.
42. th International Congress of Andrology in Montreal, Canada on June 15-19, 609-623, 2001.
43. Huber, P. R., Schnell, Y., Hering, F., and Rutishauser, G. Prostate specific antigen. Experimental and clinical observations. Scand. J. Urol. Nephrol., 104: 33-39, 1987.
44. Yeung, F., Li, X., Ellett, J., Trapman, J., Kao, C., and Chung, L. W. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J. Biol. Chem., 275: 40846-40855, 2000.
45. Schuur, E. R., Henderson, G. A., Kmetec, L. A., Miller, J. D., Lamparski, H. G., and Henderson, D. R. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem., 271: 7043-7051, 1996.
46. Snoek, R., Rennie, P. S., Kasper, S., Matusik, R. J., and Bruchovsky, N. Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides. J. Steroid Biochem. Mol. Biol., 59: 243-250, 1996.
47. Birch, M. A., Ginty, A. F., Walsh, C. A., Fraser, W. D., Gallagher, J. A., and Bilbe, G. PCR detection of cytokines in normal human and pagetic osteoblast-like cells. J. Bone. Miner. Res., 8: 1155-1162, 1993.
48. Miller, J. I., Ahmann, F. R., Drach, G. W., Emerson, S. S., and Bottaccini, M. R. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol., 147: 956-961, 1992.
49. Jacobs, S. C. Spread of prostatic cancer to bone. Urology, 21: 337-344, 1983.
50. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., and Redwine, E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 317: 909-916, 1987.
51. Sadar, M. D., and Gleave, M. E. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res., 60: 5825-5831, 2000.
52. Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., and Wilson, E. M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res., 61: 4315-4319, 2001.
53. Riegman, P. H., Vlietstra, R. J., van der Korput, J. A., Brinkmann, A. O., and Trapman, J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol., 5: 1921-1930, 1991.
54. Nazareth, L. V., and Weigel, N. L. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem., 271: 19900-19907, 1996.